Recombinant herpes simplex gb-gd vaccine

Details Recombinant herpes simplex gb-gd vaccine Recombinant herpes simplex gb-gd vaccine

C - Chemistry, Metallurgy

12

N

167/130, 195/1.3

C12N 15/38 (2006.01) A61K 39/245 (2006.01) C07K 14/035 (2006.01) C12N 1/19 (2006.01) C12N 5/10 (2006.01) C12N 15/81 (2006.01) A61K 39/00 (2006.01)

Patent

CA 1337181

Vaccines and methods for production of vaccines effective against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D and immunogenically active fragments thereof. The following E. coli HB101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain: pHS203; pHS112; pHS114; pHS127A and pHS206 were deposited on April 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on July 11, 1984, and given Accession Nos. 39762 and 39763 respectively.

478661

Affiliated with

Also associated with

Rating

Recombinant herpes simplex gb-gd vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant herpes simplex gb-gd vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant herpes simplex gb-gd vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1192010